Lupin to Present Phase 1 Data on Novel PRMT5 Inhibitor LNP7457 at ASCO 2025 Lupin Limited will unveil results from its Phase 1a trial of LNP7457, a PRMT5 inhibitor, during the ASCO annual meeting, showcasing potential cancer treatment advancements.

Lupin to Present Phase 1 Data on Novel PRMT5 Inhibitor LNP7457 at ASCO 2025 #India #Chicago #PRMT5_Inhibitor #Lupin_Limited #LNP7457